PRIVATE-LABEL MICONAZOLE AND CLOTRIMAZOLE PRODUCTS HOLD 7.2% SHARE
This article was originally published in The Tan Sheet
PRIVATE-LABEL MICONAZOLE AND CLOTRIMAZOLE PRODUCTS HOLD 7.2% SHARE of the feminine yeast infection treatment category in food and drug stores combined in the first quarter of 1994, according to a recent report by Information Resources' subsidiary Towne- Oller. The 7.2% share is more than triple the 2% share held by private-label miconazole and clotrimazole products in 1993, when such products first entered the market.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC